Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: A case-control study

Supportive Care in Cancer

Volumn 20, Issue 9, 2012, Pages 2235-2239

  Mir, Olivier ^a   Durand, Jean Philippe ^a   Boudou Rouquette, Pascaline ^a   Giroux, Julie ^a   Coriat, Romain ^a   Cessot, Anatole ^a   Ropert, Stanislas ^a   Goldwasser, François ^a   Gaillard, Raphaël ^b  

^a Institut Cochin   (France)

^b INSERM   (France)

Author keywords

Antidepressants; Antiemetics; Cancer; Cisplatin; Etoposide; Pharmacodynamics; Serotonin uptake inhibitors; Supportive care

Indexed keywords

APREPITANT; BENZODIAZEPINE; CISPLATIN; CITALOPRAM; CORTICOSTEROID; ESCITALOPRAM; ETOPOSIDE; FLUOXETINE; METHYLPREDNISOLONE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; PAROXETINE; PREDNISOLONE; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADD ON THERAPY; ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ANTIEMETIC ACTIVITY; ARTICLE; CANCER PATIENT; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DRUG POTENTIATION; DRUG USE; FEMALE; GENDER; HUMAN; MALE; MEDICAL HISTORY; PRIMARY TUMOR; PRIORITY JOURNAL; RISK ASSESSMENT; SEROTONINERGIC TRANSMISSION;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CASE-CONTROL STUDIES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ETOPOSIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; NEOPLASMS; PLATINUM; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; VOMITING;

EID: 84865195816     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1503-y     Document Type: Article

References (26)

1. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH (2011) Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol 29(31):4189-4198. doi:10.1200/JCO.2010. 34.4614
2. Durand JP, Madelaine I, Scotte F (2009) Guidelines for prophylaxis and treatment of chemotherapy-induced nausea and vomiting. Bull Cancer 96(10):951-960. doi:10.1684/bdc.2009.0924
3. Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR (2003) Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 97(11):2880-2886. doi:10.1002/cncr.11408 (Pubitemid 36605158)
4. Andrykowski MA (1990) The role of anxiety in the development of anticipatory nausea in cancer chemotherapy: a review and synthesis. Psychosom Med 52(4):458-475 (Pubitemid 20234861)
5. Martin M, Diaz-Rubio E (1990) Emesis during past pregnancy: a new prognostic factor in chemotherapy-induced emesis. Ann Oncol 1(2):152-153 (Pubitemid 20215459)
6. Morrow GR (1985) The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy. Cancer 55 (12):2766-2770 (Pubitemid 15008312)
7. Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of life and symptom control committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15(1):116-123
8. Roscoe JA, Bushunow P, Morrow GR, Hickok JT, Kuebler PJ, Jacobs A, Banerjee TK (2004) Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Programstudy of patients with breast carcinoma. Cancer 101(11):2701-2708. doi:10.1002/cncr.20718 (Pubitemid 39532305)
9. Pollera CF, Giannarelli D (1989) Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model. Cancer 64(5):1117-1122 (Pubitemid 19208867)
10. Blondeau C, Clerc N, Baude A (2002) Neurokinin-1 and neurokinin-3 receptors are expressed in vagal efferent neurons that innervate different parts of the gastro-intestinal tract. Neuroscience 110(2):339-349 (Pubitemid 34214951)
11. Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358(23):2482-2494. doi:10.1056/NEJMra0706547 (Pubitemid 351793021)
12. Massie MJ (2004) Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 32:57-71. doi:10.1093/jncimonographs/lgh014
13. Fisch MJ, Loehrer PJ, Kristeller J, Passik S, Jung SH, Shen J, Arquette MA, Brames MJ, Einhorn LH (2003) Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol 21(10):1937-1943. doi:10.1200/JCO.2003.08.025 (Pubitemid 46606381)
14. Pezzella G, Moslinger-Gehmayr R, Contu A (2001) Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. Breast Cancer Res Treat 70(1):1-10 (Pubitemid 33105097)
15. Stockler MR, O'Connell R, Nowak AK, Goldstein D, Turner J, Wilcken NR, Wyld D, Abdi EA, Glasgow A, Beale PJ, Jefford M, Dhillon H, Heritier S, Carter C, Hickie IB, Simes RJ (2007) Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled doubleblind randomised trial. Lancet Oncol 8(7):603-612. doi:10.1016/S1470-2045(07)70148-1 (Pubitemid 46995622)
16. Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, Cessot A, Coriat R, Raymond E, Mitry E, Herait P, Yataghene Y, Goldwasser F (2011) Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. doi:10.1093/annonc/mdr045
17. Loibl S, Schwedler K, von Minckwitz G, Strohmeier R, Mehta KM, Kaufmann M (2007) Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients-a double-blind, randomized study. Ann Oncol 18(4):689-693. doi:10.1093/annonc/mdl478 (Pubitemid 46523272)
18. Koriech OM (1995) Fluoxetine treatment comprises the antiemetic efficacy of ondansetron in cancer patients. Clin Oncol (R Coll Radiol) 7(6):371-372
19. Lucchelli A, Santagostino-Barbone MG, Barbieri A, Candura SM, Tonini M (1995) The interaction of antidepressant drugs with central and peripheral (enteric) 5-HT3 and 5-HT4 receptors. Br J Pharmacol 114(5):1017-1025
20. Oberg K, Akerstrom G, Rindi G, Jelic S (2010) Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 (Suppl 5):v223-v227. doi:10.1093/annonc/ mdq192
21. Sorensen M, Pijls-Johannesma M, Felip E (2010) Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v120-v125. doi:10.1093/annonc/mdq172
22. Spina E, Santoro V, D'Arrigo C (2008) Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 30(7):1206-1227
23. Janicki PK (2005) Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit 11(10):RA322-RA328 (Pubitemid 41482745)
24. Stamer UM, Lee EH, Rauers NI, Zhang L, Kleine-Brueggeney M, Fimmers R, Stuber F, Musshoff F (2011) CYP2D6- and CYP3Adependent enantioselective plasma concentrations of ondansetron in postanesthesia care. Anesth Analg 113(1):48-54. doi:10.1213/ANE.0b013e31821d01bc
25. Froger N, Gardier AM, Moratalla R, Alberti I, Lena I, Boni C, De Felipe C, Rupniak NM, Hunt SP, Jacquot C, Hamon M, Lanfumey L (2001) 5-hydroxytryptamine (5-HT)1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization. J Neurosci 21 (20):8188-8197 (Pubitemid 32952774)
26. Guiard BP, Lanfumey L, Gardier AM (2006) Microdialysis approach to study serotonin outflow in mice following selective serotonin reuptake inhibitors and substance P (neurokinin 1) receptor antagonist administration: a review. Curr Drug Targets 7 (2):187-201